16-23621428-A-G
Variant summary
Our verdict is Uncertain significance. The variant received 4 ACMG points: 4P and 0B. PM2PP3_Moderate
The NM_024675.4(PALB2):c.3047T>C(p.Phe1016Ser) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. F1016L) has been classified as Uncertain significance.
Frequency
Consequence
NM_024675.4 missense
Scores
Clinical Significance
Conservation
Publications
- hereditary breast carcinomaInheritance: AD Classification: DEFINITIVE Submitted by: ClinGen, Ambry Genetics
- Fanconi anemia complementation group NInheritance: AR Classification: DEFINITIVE, STRONG Submitted by: G2P, Labcorp Genetics (formerly Invitae), ClinGen, Ambry Genetics
- pancreatic cancer, susceptibility to, 3Inheritance: AD Classification: STRONG Submitted by: Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- familial ovarian cancerInheritance: AD Classification: MODERATE Submitted by: ClinGen
- Fanconi anemiaInheritance: AR Classification: SUPPORTIVE Submitted by: Orphanet
- hereditary nonpolyposis colon cancerInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Uncertain_significance. The variant received 4 ACMG points.
Variant Effect in Transcripts
ACMG analysis was done for transcript: NM_024675.4. You can select a different transcript below to see updated ACMG assignments.
RefSeq Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PALB2 | NM_024675.4 | MANE Select | c.3047T>C | p.Phe1016Ser | missense | Exon 10 of 13 | NP_078951.2 | ||
| PALB2 | NM_001407296.1 | c.2987T>C | p.Phe996Ser | missense | Exon 9 of 12 | NP_001394225.1 | |||
| PALB2 | NM_001407297.1 | c.2975T>C | p.Phe992Ser | missense | Exon 9 of 12 | NP_001394226.1 |
Ensembl Transcripts
| Selected | Gene | Transcript | Tags | HGVSc | HGVSp | Effect | Exon Rank | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|---|
| PALB2 | ENST00000261584.9 | TSL:1 MANE Select | c.3047T>C | p.Phe1016Ser | missense | Exon 10 of 13 | ENSP00000261584.4 | ||
| PALB2 | ENST00000568219.5 | TSL:1 | c.2162T>C | p.Phe721Ser | missense | Exon 10 of 13 | ENSP00000454703.2 | ||
| PALB2 | ENST00000561514.3 | TSL:5 | c.3053T>C | p.Phe1018Ser | missense | Exon 10 of 13 | ENSP00000460666.3 |
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Uncertain:2
The p.F1016S variant (also known as c.3047T>C), located in coding exon 10 of the PALB2 gene, results from a T to C substitution at nucleotide position 3047. The phenylalanine at codon 1016 is replaced by serine, an amino acid with highly dissimilar properties. This variant was reported in 1/98 Italian probands affected with hereditary breast and/or ovarian cancer and was not seen in 103 sporadic breast cancer cases or 102 healthy female controls (Vietri MT et al. Fam. Cancer, 2015 Sep;14:341-8). This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear.
not provided Uncertain:1
This variant is denoted PALB2 c.3047T>C at the cDNA level, p.Phe1016Ser (F1016S) at the protein level, and results in the change of a Phenylalanine to a Serine (TTT>TCT). This variant has been observed in at least one individual with a personal history of early-onset breast cancer and a family history of breast, ovarian, and pancreatic cancer (Vietri 2015). PALB2 Phe1016Ser was not observed in approximately 6,500 individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, suggesting it is not a common benign variant in these populations. Since Phenylalanine and Serine differ in polarity, charge, size or other properties, this is considered a non-conservative amino acid substitution. PALB2 Phe1016Ser occurs at a position that is conserved in mammals and is located within the region required for POLH DNA synthesis stimulation, the regions required for interaction with RAD51, BRCA2, and POLH, and within the WD-4 repeat (UniProt). In silico analyses predict that this variant is probably damaging to protein structure and function. Based on currently available evidence, it is unclear whether PALB2 Phe1016Ser is a pathogenic or benign variant. We consider it to be a variant of uncertain significance.
Familial cancer of breast Uncertain:1
This sequence change replaces phenylalanine, which is neutral and non-polar, with serine, which is neutral and polar, at codon 1016 of the PALB2 protein (p.Phe1016Ser). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individual(s) with breast cancer (PMID: 25666743). ClinVar contains an entry for this variant (Variation ID: 420578). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt PALB2 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance.
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at